We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

DYMIND BIOTECHNOLOGY

Dymind designs, manufactures and sells a range of auto hematology analyzers and home ventilator. The company also off... read more Featured Products: More products

Download Mobile App





Dymind Presents Advanced Automatic Hematology Analysis Line

By LabMedica International staff writers
Posted on 06 Feb 2025

Dymind Biotechnology (Shenzhen, China) is presenting its comprehensive range of healthcare solutions at Medlab Middle East 2025, covering the fields of hematology, coagulation, immunoassay, POCT and veterinary. More...

Dymind is presenting the DH-8000 advanced hematology analysis workstation that provides a comprehensive testing solution for whole blood, capillary blood, body fluids, and pre-diluted samples. It is designed to enhance the user's experience in high-volume sample testing, by minimizing manual intervention and maximizing efficiency. Dymind is also showcasing the upgraded DH-800 auto hematology analyzer with AI technology that provides more accurate and efficient diagnosis. Also featured at the event is the MF1280 novel multiplex platform for allergy and autoimmunity testing that delivers rapid results for all tested items within a single test portfolio, significantly increasing diagnostic efficiency.

At the 2025 edition of Medlab Middle East, Dymind is highlighting the CA1200 fully automated coagulation analyzer that combines the optical and mechanical methods for clotting assays, while being able to intelligent switch from two methods when an abnormal sample is detected, to ensure both test accuracy and cost-effectiveness. In addition, Dymind is showcasing the innovative DP-H50 automatic 5-part hematology analyzer that integrates immunoassay and chemistry. With capabilities for joint tests in CBC, immunofluorescence, colloidal gold, and the chemistry module, the DP-H50 offers 5 test modes with single-package reagents to meet diverse demands. Among its veterinary solutions, Dymind is showcasing the automatic AI morphology analyzer, the D-wise, 5-part automatic hematology analyzer with RET, DM61 Vet, and DP-H10 Vet POCT hematology analyzer.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.